Merck KGaA Health Care Head Happy With Old And New Mix

Pipeline Will Augment Established Strong Sellers

The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.

Guenter_Peter
Peter Guenter

When Merck KGaA presented its financials for 2021 last month, it was striking to see that a number of drugs that got their first approvals last century were still making very healthy contributions to the German group's sales.

While Merck touted growth from newer products such as the multiple sclerosis tablet Mavenclad (claribine) and the checkpoint inhibitor Bavencio...

More from Business Strategy

More from In Vivo